Korean Pharmaceutical Bio Association to strengthen local networking by attending the Korean-American Pharmaceutical Association
Jun 16, 2025
|
Korean scientists working in pharmaceutical bio companies, academia, and regulatory agencies across the United States are participating in KASBP, an organization established for the growth and development of the Korean-American pharmaceutical industry. The association signed an MOU with KASBP to promote mutual cooperation in 2019.
The symposium was held under the theme of 「Clinical Development Success Strategy」 (Overcoming Regulatory Hurdle and Promoting Innovation). Examiners from the U.S. Food and Drug Administration (FDA), the National Institute of Health (NIH), and experts from pharmaceutical bio companies in Korea and the United States attended to introduce the latest regulatory trends and new drug development trends.
Chairman Noh Yeon-hong said in his keynote speech that `Korea's pharmaceutical bio industry has achieved remarkable growth in recent years and is approaching global levels in various indicators such as new drug pipelines, technology transfer, and biopharmaceutical production capacityBased on the convergence of advanced technologies such as AI and big data, pharmaceutical bio is emerging as another national strategic industry connecting semiconductors, so we look forward to active cooperation with Korean American scientists for the leap forward of the Korean pharmaceutical bio industry," he said.
Meanwhile, Roh also held a meeting with executives of the Korean-American Professional Association in Life Sciences, another Washington, D.C.-based group of Korean-American life scientists, on the 13th. We talked with executives, including Chairman Park Ji-hoon of KAPAL, on the latest regulatory development trends and what they want from the government and association, and decided to use the association's open innovation platform, K-SPACE, to strengthen the introduction of U.S. regulatory trends and sharing of necessary information when entering the market. The association previously signed a 2022 MOU with KAPAL.
In addition, Chairman Roh held a meeting with officials from Korean biotech companies that entered Maryland, including D&D Pharmatech, Sotirion Bio and Kyros Bio Consulting, and discussed the need to expand their presence in the country and the direction of support from the government and associations. He then visited the Germantown Innovation Center (GIC), Maryland's leading bio-cluster complex, and discussed ways to expand mutual expansion of companies from both countries.
`In order for the domestic pharmaceutical bio industry to become a global player beyond the limits of the domestic market, expansion of entry into promising clusters in the U.S. and exchanges with local experts and Korean American scientists are essential,' Roh said. `The association will actively seek practical cooperation measures.'
Reporter Kim So-hyung compact@sportschosun.com
This article was translated by Naver AI translator.
